(probability ratio = 1). In usual hospital-based studies, S vi and S ui are approximated by hS vi vs hS ui , the numbers of persons who visit clinics or hospitals. The tendency to visit a clinic or hospital (hS=S) may differ between vaccinated and unvaccinated people in accordance with their healthcare-seeking attitudes. Usually hS=S is thought to be larger in vaccinated people than in unvaccinated people, so that the probability ratio would be biased towards 1 (ie, VE would be underestimated).
In a case-control study, VE is evaluated as the ratio of odds of vaccinations among cases to the odds among controls (ie, those who did not develop the disease; note that VE = 1 − odds ratio). So, the odds ratio is (S vi =S ui )=((V − S vi )=(U − S ui )) in accordance with the probability ratio in a prospective study. Practical definitions of cases and controls vary by study design, especially for controls. In a hospital-based case-control study, cases are randomly selected from patients who visit clinics or hospitals and are diagnosed as being infected with the pathogens and having symptoms, so that the odds of vaccination among cases is hS vi =hS ui . As hS=S is thought to be larger in vaccinated people as aforementioned, the odds tend to be larger than the typical odds of S vi =S ui . If controls are randomly selected from hospital patients who neither become infected with the pathogens nor develop the symptoms of the target disease (ie, hN vn and hN un ), the tendency to visit a clinic or hospital (hN=N) is thought to vary according to the illness that led to seeking care. So, the direction of confounding by a healthcare-seeking attitude that is determined by hN=N and hS=S cannot be predicted.
In a case-control study with the test-negative design, controls are randomly selected from patients having symptoms that are similar to those of the target disease but who are not infected with the target pathogens (ie, hS vn and hS un ). Then, the odds of vaccination among controls are estimated as hS vn =hS un . Here, hS=S in vaccinated patients can be assumed to be the same between symptomatic patients with and without infection (hS vi =S vi = hS vn = S vn , set to be P v ) because patients do not know their infection status before visiting clinics or hospitals. The situation is the same in unvaccinated patients (hS ui =S ui = hS un =S un , set to be P u ). There-fore, the odds ratio estimating the VE in the test-negative design is (hS vi =hS ui )=(hS vn =hS un ), which can be transformed to (P v S vi = P u S ui )=(P v S vn =P u S un ) = (S vi =S ui )=(S vn =S un ), so that the difference in hS=S between vaccinated and unvaccinated people due to their healthcare-seeking attitude cancels.
Note that a healthcare-seeking attitude may have more complex implications in actual settings. But, the above-mentioned flow is useful for generally understanding how the test-negative design can minimize confounding by a healthcare-seeking attitude in case-control studies. During the previous decade, there has been a growing number of VE studies using the test-negative design, especially with influenza and rotavirus infections. These diseases share the characteristic that patients are likely to visit a clinic or hospital immediately after the onset of related symptoms (influenza-like illness for influenza and gastrointestinal symptoms for rotavirus infection). This characteristic enables us to apply the test-negative design with the simplified scenario of a healthcareseeking attitude. In other words, applicability of the test-negative design depends on this characteristic (rapidly seeking medical attention). Figure 2 shows an outline of the test-negative design for VE studies of influenza and rotavirus infection, illustrating retrospective flow opposite to that of Figure 1 . Patients who are eligible for the study are all who visit clinics or hospitals with influenza-like illness or gastrointestinal symptoms during an epidemic period, who meet the inclusion criteria of the study. It is essential for the test-negative design that symptoms defined as criteria for inclusion in the study should be clearly specified in advance to ensure that cases and controls have similar probabilities of visiting clinics or hospitals with regard to symptoms and healthcare-seeking attitude prior to actual diagnosis. It is also essential that, at the procedure "recruitment and test" ( + on Figure 2 ), all eligible patients (or a subset of eligible patients who are selected in a random or systematic manner) have to be recruited in the study and all study subjects (or a subset who are selected in a random or systematic manner) have to be tested; if not, sampling bias would occur. Finally, the subjects are classified into either cases or controls according to their test results for influenza or rotavirus infection. VE can be estimated as (1 − odds ratio) × 100 (%) with reduced influence of a healthcare-seeking attitude.
For many clinicians, it is likely that the test-negative design is easier to conduct than traditional case-control studies. Control selection is technically complicated in traditional case-control studies, whereas subjects who have negative test results are automatically categorized as controls in the test-negative design. This means that, in the test-negative design, investigators do not need to pay attention to whether or not the controls are selected appropriately under the specific study hypotheses. Such convenience sometimes leads to careless planning of a test-negative design without an understanding of the basic principles of epidemiology. Typical examples include influenza VE studies in Japan using information from clinician-ordered rapid diagnostic testing results in a pre-existing medical database. Since the study Test-Negative Design subjects are limited to those who received the clinician-ordered test in a routine clinical setting, application of the test would depend on the likelihood of having influenza (outcome) or influenza vaccination status (exposure), resulting in biased sampling (non-representativeness) of the study subjects even if the study subjects meet the inclusion criteria. For example, if clinicians order the diagnostic test for patients with severe influenza-like illness (ie, those with a high likelihood of having influenza), the proportion of unvaccinated persons among cases is likely to increase, leading to overestimation of VE. In order to avoid selection bias in the test-negative design, it is important to employ both "active recruitment of study subjects from the eligible patients according to pre-defined disease criteria" and "active application of the test to the study subjects" in a random or systematic manner irrespective of exposure and outcome status. 4 A study from the United States found potential selection bias in recruitment of patients with symptoms of influenza-like illness in influenza VE studies using the test-negative design with clinician-ordered rapid diagnostic testing and indicated the importance of active unbiased recruitment of study subjects according to pre-defined symptoms and systematic testing. 5 In Araki's test-negative study regarding rotavirus VE, they also emphasized that the pathogenic test should be applied to all eligible patients visiting with pre-defined symptoms. 1 Although the test-negative design is a novel modification of the traditional case-control study that reduces the biasing effect of a healthcare-seeking attitude, it is useful to understand its concept in relation to the basic principles of epidemiology. To appropriately use the test-negative design in clinical settings, guidance from epidemiologists is needed. See more detailed theoretical discussion on confounding, selection bias, and measurement error in the papers by Sullivan et al 6 . So, all eligible patients (or a subset of eligible patients who are selected in a random or systematic manner) have to be recruited in the study and all study subjects (or a subset who are selected in a random or systematic manner) have to be tested. If the study subjects are limited to those who received the clinicianordered test in a routine clinical setting, the application of the test would be related to the likelihood of having the disease under investigation (outcome) or vaccination status (exposure), resulting in biased sampling (nonrepresentativeness) of the study subjects even if the study subjects meet the inclusion criteria. 
